

28th December 2021

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Corrigendum to the Press Release

Dear Sir / Madam,

In reference to the press release titled “Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu[®] (Molnupiravir 200 mg) in India to treat mild to moderate COVID-19 at high risk of developing severe disease” issued on 28th December 2021, the Company would like to clarify that it has received EUA to launch Cipmolnu[®] (Molnupiravir 200 mg) in India for treatment of adult patients with COVID-19, with SpO₂>93% and who have high risk of disease progression including hospitalization or death.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode